Insulin: New Products, New Strategies

This monograph has been designed to enhance the healthcare professional’s knowledge and understanding of new insulin products and diabetes treatment strategies. It is intended for pharmacists, nurses, and dietitians who work with or anticipate working with patients with diabetes who may require insulin. Discussed in the program are the impact of the disease, insulin formulations, insulin analogs, dosing regimens, and available alternatives for insulin administration. The benefits of tight glycemic control and techniques for minimizing problems associated with insulin therapy are identified and described.

Goal
To enhance the healthcare professional's knowledge and understanding of new insulin products and diabetes treatment strategies.

Objectives
After reading this monograph, the participant should be able to do the following:

Describe the impact of diabetes on health in the United States.
Explain the relationship between insulin and glucose in the body.
Distinguish among the different insulin formulations.
Describe the basics of insulin-dosing regimens.
Describe alternative methods available for insulin administration.
Discuss the benefits of tight glycemic control and be able to explain to patients the rationale and methods for maintaining good glycemic control.
Identify and describe "troubleshooting" techniques for the patient and caregiver team to use in minimizing problems associated with insulin therapy.

Pharmacists

Novo Nordisk Pharmaceuticals Inc. and The FCG Institute for Continuing Education are approved by the American Council on Pharmaceutical Education as providers of continuing pharmaceutical education and comply with the Criteria for Quality for continuing education programming.Certification will be awarded based on successful completion of the post-test (70% or better).

This program is acceptable for 1.5 credits (0.15) CEUs in states that recognize ACPE-approved providers.
ACPE ID # 360-086-00-001-H01. This program expires 11/1/03.

Editorial Advisory Board
Mary Anne Koda-Kimble, PharmD, CDE
Dean and Professor of Clinical Pharmacy
School of Pharmacy University of California-San Francisco

Virginia Peragallo-Dittko, RN, MA, CDE
Diabetes Nurse Specialist
Program Director
Winthrop-University Hospital
Mineola, New York

Target Audience
This CE program is intended for pharmacists and nurses who work with or anticipate working with patients with diabetes who may require insulin.

Fee
There is no fee to receive credits for this program.

Educational Grantor
This program has been supported through an unrestricted educational grant from Novo Nordisk Pharmaceuticals, Inc.

Novolin Prefilled, PenFill, NovoLog, NovoPen, Novolin, Velosulin, Lente, Ultralente are trademarks of Novo Nordisk A/S. Humalog, HumalogMix 75/25, Humulin, Iletin are trademarks of Eli Lilly and Company. Lantus is a trademark of Aventis Pharmaceuticals Inc. B-DPen is a trademark of Becton Dickinson. Avandia is a trademark of Smithkline Beecham Pharmaceuticals. Actos is a trademark of Takeda Chemical Industries, LTD. Rezulin is a trademark of Parke-Davis/Warner-Lambert. Glucophage is a trademark of Bristol-Myers Squibb Company

Pharmacists Click Here to Continue